The first FDA-approved oral GLP-1 for weight loss is now available to U.S. patients for $299 per month through a self-pay platform.
Self-paying patients can order the Wegovy pill at $149 per month as they work up to the two highest doses, which are available at $299 per month, according to a Jan. 5 news release from Novo Nordisk, a drugmaker based in Denmark.
Approved Dec. 22, the daily pill is indicated to reduce excess body weight, maintain long-term weight loss and lower the risk of major adverse cardiovascular events, including death, heart attack and stroke. In a phase 3 trial, adults taking daily Wegovy pills achieved an average weight loss of 14% after 64 weeks, according to Novo Nordisk. The study included 307 participants.
Eli Lilly is waiting for FDA approval of its experimental GLP-1 pill, orforglipron, and an answer is expected early in 2026. Orforglipron led to an average weight loss of 12.4%, or 27.3 pounds, in a 72-week, phase 3 trial involving more than 3,000 adults.
The traditional form of GLP-1 therapies is a weekly injectable solution.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
